Zuoli Pharmaceutical: Announcement of Resolutions of the 17th (Provisional) Meeting of the 8th Board of Directors
Securities code: 300181 Securities abbreviation: Zuoli Pharmaceutical Announcement number: 2026-050
Zhejiang Zuoli Pharmaceutical Co., Ltd.
Announcement of Resolutions of the 17th (Extraordinary) Meeting of the 8th Board of Directors
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete, and contains no false records, misleading statements or major omissions.
1. Convening of board of directors meetings
The 17th (temporary) meeting of the 8th Board of Directors of Zhejiang Zuoli Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") was held on July 21, 2026 in the company's conference room through a combination of on-site and communication voting. The meeting notice will be delivered to all directors on July 16, 2026, by a combination of personal delivery, telephone, fax and email. 9 directors should be present at the meeting, and 9 directors were actually present (including independent directors Mr. Zhu Jian and Mr. Wang Ping who reviewed and voted by communication voting). This meeting was chaired by Chairman Yu Youqiang, and the company's board secretary and other company executives attended the meeting. The meeting was held in compliance with the relevant provisions of the Company Law of the People's Republic of China and the Articles of Association.
2. Review status of board of directors meeting
- Considered and approved the "Proposal on the Achievements of the Vesting Conditions for the First Vesting Period of the Reserved Grant Part of the 2024 Restricted Stock Incentive Plan"
According to the relevant provisions of the company's "2024 Restricted Stock Incentive Plan (Draft)", the vesting conditions for the first vesting period of the reserved grant portion of the company's 2024 restricted stock incentive plan have been met. There are a total of 8 incentive objects that meet the vesting conditions, and a total of 300,000 vestable restricted stocks, accounting for 0.04% of the current total share capital of the company. Agree to handle matters related to the vesting of restricted stocks in the first vesting period for some of the reserved incentive recipients.
For details, please refer to the relevant announcement disclosed by the company on the GEM information disclosure website designated by the China Securities Regulatory Commission on the same day.
This proposal has been reviewed and approved by the Remuneration and Appraisal Committee of the Board of Directors.
Related directors Wang Tao and Feng Guofu abstained from voting.
Voting results: 7 votes in favor, 0 votes against, 0 abstentions, passed.
- Considered and approved the "Proposal on the Expiration of the First Lock-up Period and Achievement of Unlocking Conditions for the Initial Grant Part of the Employee Stock Ownership Plan in 2024"
According to the relevant provisions of the "Guiding Opinions on the Pilot Implementation of Employee Stock Ownership Plans by Listed Companies", "Shenzhen Stock Exchange Self-Regulatory Supervision Guidelines for Listed Companies No. 2 - Standardized Operations of GEM Listed Companies" and the company's "2024 Employee Stock Ownership Plan" and "2024 Employee Stock Ownership Plan Management Measures", the first lock-in period for the first grant part of the company's 2024 employee stock ownership plan has already started on July 14, 2026. On the expiration of the date, the board of directors believes that the unlocking conditions for the first lock-up period of the initial grant have been met. A total of 110 people who meet the unlocking conditions of the lock-up period can unlock 40% of the total number of initial grants of the employee stock ownership plan in accordance with relevant regulations. The corresponding number of unlockable shares is 2.39 million shares, accounting for 0.34% of the company's current total share capital.
For details, please refer to the relevant announcement disclosed by the company on the GEM information disclosure website designated by the China Securities Regulatory Commission on the same day.
This proposal has been reviewed and approved by the Remuneration and Appraisal Committee of the Board of Directors.
Related directors Wang Tao and Feng Guofu abstained from voting.
Voting results: 7 votes in favor, 0 votes against, 0 abstentions, passed.
3. Documents for reference
Resolution of the 17th (extraordinary) meeting of the 8th Board of Directors;
Resolution of the eighth meeting of the Remuneration and Appraisal Committee of the eighth board of directors;
Other documents required by Shenzhen Stock Exchange.
Announcement is hereby made.
Board of Directors of Zhejiang Zuoli Pharmaceutical Co., Ltd.
July 21, 2026